Nicholas Wysham, MD
Pulmonary Disease · Vancouver, WANPI 1144464496
Payments from drug & device makers
What this record shows
This record is dominated by education: $73,581 of the $116,969 with a category attached, or 62.9%. Intuitive Surgical accounts for 92.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $67,202 and has fallen 97.5% since, to $1,696 in 2025. Among pulmonary disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $606.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$108K
- AstraZeneca$3K
- Verathon Inc.$3K
- Pulmonx Corporation$1K
- ERBE USA Inc$752
- Boehringer Ingelheim$276
- plus $501 from 10 others
Across 73 payments — averaging $1095.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$26K
- Chiesi USA, Inc.$19K
- AstraZeneca$16K
- Regeneron$15K
- GSK$5K
What the payments were for
- Consulting fees$5,6235%
- Speaking & faculty fees$19,25016%
- Travel & lodging$8,9608%
- Food & beverage$9,4058%
- Education$73,58163%
- Gifts$1510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 148 | $108,110 |
| AstraZeneca | 12 | $3,020 |
| Verathon Inc. | 4 | $3,000 |
| Pulmonx Corporation | 9 | $1,309 |
| ERBE USA Inc | 3 | $752 |
| Boehringer Ingelheim | 5 | $276 |
| GSK | 1 | $123 |
| Sunovion Pharmaceuticals Inc. | 1 | $123 |
| Philips North America LLC | 1 | $68 |
| Genentech, Inc. | 1 | $40 |
| Insmed, Inc. | 2 | $34 |
| Canon Medical Systems USA, Inc. | 2 | $32 |
| Regeneron | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Vapotherm Inc | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$89,196
- DA VINCI SP$17,663
- Bronchoscope$2,000
- FASENRA$1,773
- B Flex$1,000
- ZEPHYR ENDOBRONCHIAL VALVE$841
- CRYO2$486
- vio3 apc3 cryo2$247
- TAGRISSO$125
- NUCALA$123
- OFEV$121
How this compares
$116,969 in reported general payments places this provider in the 95th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 185 | $187,086 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 87 | $99,331 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 63 | $63,577 |
| Spiriva RespimatTiotropium Bromide | 58 | $56,181 |
| Dupixent SyringeDupilumab | 14 | $52,021 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $22,633 |
| DuleraMometasone/Formoterol | 38 | $21,047 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 50 | $14,159 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $13,365 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $13,191 |
| BreynaBudesonide/Formoterol Fumarate | 24 | $7,300 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 188 | $6,177 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $6,040 |
| Roflumilast | 61 | $5,950 |
| Ventolin HfaAlbuterol Sulfate | 14 | $986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $123 | $213,642221 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,020 | $121,964147 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $276 | $119,758121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Vancouver
- Todd GienappVancouver$6K
- Bhanu PatibandlaVancouver$4K
- Jed GordenSeattle$236K
- Dominique PepperOlympia$212K
- Jiten PatelSpokane$200K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
- Colleen OverdorfBellingham$110K
- Jeffrey CarySeattle$106K
- Benjamin SyBremerton$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.